South Korean contract development and manufacturing organization (CDMO) Samsung Biologics has embarked on a significant phase of global expansion, marked…
Read More
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX Therapeutics have significantly expanded their strategic research and licensing collaboration, aiming to pioneer the development of…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company is embarking on a significant acquisition spree, exemplified by its recent agreement to acquire Kelonia Therapeutics…
Read More
Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal
Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently riding an unprecedented wave of success fueled by its GLP-1 franchise, has announced its intent…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently buoyed by the explosive success of its GLP-1 franchise, has announced its intent to acquire…
Read More
EU Strikes Landmark Deal on Critical Medicines Act to Fortify Pharmaceutical Sector and Ensure Patient Supply
The European Union (EU) has achieved a significant legislative milestone with the provisional agreement on the Critical Medicines Act (CMA),…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, a pharmaceutical giant currently experiencing unprecedented growth driven by its blockbuster GLP-1 agonists, has announced its…
Read More
GSK Secures Promising Metabolic Oligonucleotide Therapy Rights from SiranBio in Up to $1 Billion Deal
In a significant move to bolster its pipeline and solidify its strategic focus on the complex challenges of obesity, global…
Read More
Chinese Biotechs Emerge as Global Pharma Powerhouses, Securing One-Third of Major Deal Value in 16 Months
Over the past sixteen months, Chinese-domiciled biotechnology companies have solidified their position as pivotal players in the global pharmaceutical landscape,…
Read MoreYOU MAY HAVE MISSED
